Faculty: Emma Guttman-Yassky, MD, PhD; Robert E. Kalb, MD; Jeffrey M. Weinberg, MD
The goal of this Clinical Research Updates™ activity is to educate clinicians on atopic dermatitis pathoetiology, best practices in patient evaluations, and the clinical profiles of treatment options for moderate-to-severe disease, including a biologic therapy recently approved by the US Food and Drug Administration (FDA). With the overall goal of improving outcomes for patients with moderate-to-severe atopic dermatitis, this educational activity integrates published clinical data and the experience of expert faculty to provide actionable recommendations on individualizing care and improving patient-clinician communication. Atopic dermatitis is a chronic inflammatory condition with manifestations in the skin and in other organ systems throughout the body. Increasing in prevalence over the last 2 decades, the disease places tremendous burdens on patients, caregivers, and other family members. Our evolving understanding of disease pathophysiology and widespread effects on patient health and quality of life highlight the need for prompt diagnosis and proactive management. Moreover, research into the mechanisms underlying atopic dermatitis pathogenesis and progression has led to new approaches for disease characterization and treatment.
View this program in its entirety here [ Ссылка ]
You can also visit [ Ссылка ] for access to additional video content as well as free CME activities in various therapeutic areas.
